{"disease":{"id":"tolerance","name":"tolerance"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active ankylosing spondylitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of acute pyelonephritis (APN) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated cystitis caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated cystitis caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"fentanyl","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"morphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"morphine-sulfate","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"oxymorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"ponatinib-hydrochloride","indication_name":"CP-CML with resistance or intolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PONATINIB HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Ponatinib inhibits multiple kinases, including ABL and its T315I mutant, reducing tumor size in mice."},{"drug_id":"oxycontin","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"hydromorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"fentanyl-f2","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"lactose","indication_name":"Lactose intolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilactose","generic_name":"Lactose","company_name":"Kantonsspital Aarau","drug_phase":"marketed","molecular_target":"Galectin-9","drug_class":"lactose","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"oxycodone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial sinusitis (ABS) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of community-acquired pneumonia (CAP) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute pyelonephritis (APN) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."}],"pipeline":[],"offLabel":[],"totalMarketed":39,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05121844","title":"Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31187,"lead_sponsor_name":"Signos Inc","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05874635","title":"Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Signos Inc","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00829660","title":"Acarbose Cardiovascular Evaluation Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":6526,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06958640","title":"Da Qing Offspring Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT04585204","title":"Comparison of the Detection Rates of 50 Gr-100 Gr OGTT and 75 Gr OGTT That Require Medical Treatment of GDM","phase":"NA","overall_status":"RECRUITING","enrollment_count":2282,"lead_sponsor_name":"Ankara City Hospital Bilkent","has_results":false},{"nct_id":"NCT06286488","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT05076227","title":"Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity","phase":"","overall_status":"COMPLETED","enrollment_count":1206,"lead_sponsor_name":"Serge Thal","has_results":false},{"nct_id":"NCT03261856","title":"Clinical Utility of Breath Tests in GI","phase":"","overall_status":"COMPLETED","enrollment_count":1080,"lead_sponsor_name":"Augusta University","has_results":false},{"nct_id":"NCT07085455","title":"The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN)","phase":"NA","overall_status":"RECRUITING","enrollment_count":946,"lead_sponsor_name":"Dong Zhang","has_results":false},{"nct_id":"NCT02309138","title":"Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)","phase":"NA","overall_status":"COMPLETED","enrollment_count":921,"lead_sponsor_name":"Esa M Davis, MD MPH FAAFP","has_results":true},{"nct_id":"NCT03506581","title":"Dysfunctional Adiposity and Glucose Impairment","phase":"","overall_status":"COMPLETED","enrollment_count":853,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT01993927","title":"Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"","phase":"","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03623412","title":"Women With Minor Degrees of Glucose Intolerance and the Postpartum Glucose Tolerance Test","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Clalit Health Services","has_results":false},{"nct_id":"NCT04943926","title":"Dietary Strategies for Remission of Type 2 Diabetes","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Bergen","has_results":false},{"nct_id":"NCT05022420","title":"SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03393793","title":"HEart trAnsplantation Registry of piTie-Salpetriere University Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":566,"lead_sponsor_name":"Lee S Nguyen","has_results":false},{"nct_id":"NCT03597516","title":"Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"Ritter Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05566613","title":"Prediction of Individual Radiosensitivity During Radiotherapy for Breast Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT03725033","title":"Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":538,"lead_sponsor_name":"Materia Medica Holding","has_results":true},{"nct_id":"NCT05180201","title":"SEPSIS: L. Plantarum Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":519,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT01839448","title":"Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT07145580","title":"Combined Lactulose H2-breath Test With Abdominal Imaging","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Klinik Arlesheim","has_results":false},{"nct_id":"NCT06553729","title":"Effects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT03103113","title":"The Evolution of Relationship Between Results of Peripheral Blood Test and Outcomes of in Vitro Fertilization","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Yeh","has_results":false},{"nct_id":"NCT07521111","title":"Predictive Value of Gastrointestinal Blood Flow for Enteral Nutrition Intolerance in Critically Ill Patients","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05284578","title":"The Effects of Expressive Writing and Compassionate Letter Writing on Emotional Distress Intolerance","phase":"NA","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"University of Waterloo","has_results":false},{"nct_id":"NCT03216993","title":"An Early Enteral Nutrition Protocol in Shanghai","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05745792","title":"Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07286747","title":"Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":390,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT03698058","title":"A2 GUM Post-Market Effectiveness Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Société des Produits Nestlé (SPN)","has_results":false},{"nct_id":"NCT06495814","title":"Characterization and Mechanism Research of the Pre-disease State of Obese Type 2 Diabetes Mellitus","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":380,"lead_sponsor_name":"Fengmei Lian","has_results":false},{"nct_id":"NCT05056376","title":"Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs","phase":"NA","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT04105686","title":"Growth and Tolerance of Young Infants Fed Infant Formula","phase":"NA","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Abbott Nutrition","has_results":false},{"nct_id":"NCT06870318","title":"Enrichment of Human Milk With Human and Bovine Milk-based Fortifiers for Very Preterm Infants: a Meta-analysis","phase":"","overall_status":"COMPLETED","enrollment_count":355,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT03085277","title":"Bovine Colostrum for Preterm Newborns","phase":"NA","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Per Torp Sangild","has_results":false},{"nct_id":"NCT04383132","title":"Effectiveness of Abdominal Binder Use During Colonoscopy","phase":"NA","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","has_results":true},{"nct_id":"NCT03426228","title":"In Vitro Fertilization Impact on Metabolic Parameters","phase":"","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"University of Warwick","has_results":true},{"nct_id":"NCT06503952","title":"Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst: a Matched Controlled Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":340,"lead_sponsor_name":"Matricelab Innove","has_results":false},{"nct_id":"NCT06548828","title":"Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":324,"lead_sponsor_name":"George Washington University","has_results":false},{"nct_id":"NCT03597113","title":"Evaluation of Infants Fed an Extensively Hydrolyzed Hypo Allergenic Infant Formula","phase":"","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Abbott Nutrition","has_results":false},{"nct_id":"NCT04144595","title":"Association Between Low Plasma Glucose After Oral Glucose Tolerance Test in Pregnancy With Impaired Fetal Growth","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Hospital Universitario Dr. Jose E. Gonzalez","has_results":false},{"nct_id":"NCT05555771","title":"Paediatric Syncope in the Emergency Department","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Dr. Victoria Claydon","has_results":false},{"nct_id":"NCT03548324","title":"Enteral Nutrition Tolerance And REspiratory Support (ENTARES)","phase":"NA","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"University of Turin, Italy","has_results":false},{"nct_id":"NCT05619653","title":"Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":279,"lead_sponsor_name":"Valentina Puentmann","has_results":false},{"nct_id":"NCT05121935","title":"MAL-ED Metabolic: A Follow-Up of Chronic Disease at Puberty","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":254,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT03537365","title":"Bovine Colostrum as a Fortifier Added to Human Milk for Preterm Infants","phase":"NA","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Per Torp Sangild","has_results":false},{"nct_id":"NCT02779972","title":"Age Related Changes in Cardiac Physiology as a Predictor of Exercise Tolerance","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT07296718","title":"Single Vs Multi-strain Probiotics for Preterm Neonates","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"Madiha, MPhil","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}